Subscribe

Discontinuation of Doxorubicin and Dexrazoxane for Myocardial Dysfunction

Specialty:

Hematology Oncology
Clinical Pharmacology

Objective:

ICD-10:

Description:

Dexrazoxane can reduce the risk of cardiotoxicity from continued doxorubicin therapy but some patients may develop this complication. Doxorubicin plus dexrazoxane therapy should be discontinued if there is evidence of left ventricular dysfunction.

To read more or access our algorithms and calculators, please log in or register.

RECENT TWEETS

medal descover
medal iphone